@biopharmacaster Historic milestone in a fatal disease.A nonambulatory Friedreichโs Ataxia (FA) patient regained the ability to walk after Nomlabofusp treatment. The market is overlooking these remarkable data. Patience rewards investors. Disease-modifying potential is becoming increasingly clear